AUTHORS
Tamer Othman, MD, Arthur Li2, Jose Tinajero, PharmD3, Vaibhav Agrawal, MD4, Joo Song, MD5, Zhaohui Gu, PhD6, Paul Koller, MD7, Hoda Pourhassan, MD8, Yazeed Samara, MD9, Dat Ngo, PharmD10, Rick Y. Lin, MD11, Karamjeet Singh Sandhu, MD12, Monzr M. M Al Malki, MD13, Ahmed Aribi, MD14, Salman Otoukesh, MD15, Brian John Ball, MD, MS16, Andrew Artz, MD,MS17, Amandeep Salhotra, MD18, Samer Khaled, MD19, Amanda Blackmon, DO20, Idoroenyi Amanam, MD21, Haris Ali, MD22, Sunmin Park, MD PhD23, Julio Alvarenga Thiebaud, MD24, Karam Ashouri25, Pamela S. Becker, MD, PhD26, Ryotaro Nakamura, MD27, Guido Marcucci, MD28, Anthony Selwyn Stein, MD29, Stephen J. Forman, MD30, Vinod Pullarkat, MD31, Ibrahim Aldoss, MD32
AFFILIATIONS
1 City of Hope, Irvine, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, United States
7 City of Hope, Duarte, United States
8 City of Hope, Duarte, United States
9 City of Hope, Duarte, United States
10 City of Hope, Duarte, United States
11 City of Hope, Duarte, United States
12 City of Hope, Duarte, United States
13 City of Hope, Duarte, United States
14 City of Hope, Duarte, United States
15 City of Hope, Duarte, United States
16 City of Hope, Duarte, United States
17 City of Hope, Duarte, United States
18 City of Hope, Duarte, United States
19 City of Hope, Duarte, United States
20 City of Hope, Duarte, United States
21 City of Hope, Duarte, United States
22 City of Hope, Duarte, United States
23 City of Hope, Duarte, United States
24 City of Hope, Duarte, United States
25 City of Hope, Duarte, United States
26 City of Hope, Duarte, United States
27 City of Hope, Duarte, United States
28 City of Hope, Duarte, United States
29 City of Hope, Duarte, United States
30 City of Hope, Duarte, United States
31 City of Hope, Duarte, United States
32 City of Hope, Duarte, United States
ABSTRACT
Background
Adult Ph- B-ALL is genetically heterogeneous, yet the prognostic significance of recurrent somatic mutations beyond the 2022 ICC classification remains unclear. We evaluated the association of non-ICC-defining biologically relevant mutational pathways identified by routine next generation sequencing NGS with treatment response and survival across contemporary therapies.
Methods
We retrospectively analyzed adults with Ph- B-ALL who underwent routine NGS and treated at City of Hope. Alterations were categorized into TP53, myeloid-associated (TET2, DNMT3A, ASXL1, RUNX1, BCOR, BCORL1, CUX1, CBL, IDH1, IDH2, SRSF2, SF3B1, U2AF1, ZRSR2, SMC1A, SMC3), RTK/RAS, cell-cycle, and epigenetic pathways as defined by the Cancer Genome Atlas. Outcomes included complete remission (CR), multiparameter flow cytometry measurable residual disease (MFC MRD) negativity, event-free survival (EFS), and overall survival (OS). Logistic regression, Kaplan–Meier methods, and Cox proportional hazards models were used.
Results
A total of 445 adult patients were included (median age 41 years; 59.8% male; 68.8% Hispanic). The most common ICC subtypes were BCR::ABL1-like, JAK-STAT activated (n=171 ; 38.4%) and B-ALL, NOS (n=147; 33.0%). Among B-ALL, NOS, 62.6% met NCCN poor-risk criteria. TP53 alterations were identified in 20.9% of patients, while RTK/RAS (34.6%), cell-cycle (26.1%), epigenetic (18.7%), and myeloid-associated (10.8%) alterations were the most common pathway-level abnormalities. The most frequent individual alterations included KRAS (14.8%), NRAS (12.8%), CDKN2A/B (24.5%), and KMT2D (9.9%). Pediatric-inspired regimens (PIR) (54.2%) and Hyper-CVAD (hCVAD) (25.2%) were the predominant frontline therapies; 41.1% received blinatumomab (blin) in the relapsed/refractory (R/R) or frontline induction setting, 33.5% inotuzumab (InO), 26.1% CAR T-cell therapy, and 57.5% underwent allogeneic transplant (HCT) during their treatment course.
Patients with TP53 alterations treated with frontline hCVAD had higher CR rates than TP53 wild-type patients (91.2% vs. 65.4%, p=0.005). Myeloid-associated alterations predicted higher CR rates with blin in the R/R or frontline induction setting (76.2% vs. 50.3%, p=0.026), whereas cell-cycle alterations were associated with lower CR rates with blin (36.7% vs. 59.8%, p=0.006) and InO (34.1% vs. 52.5%, p=0.041). Cell-cycle alterations were associated with higher MFC MRD negativity following frontline PIR (81.4% vs. 66.9%, p=0.043).
In univariable analyses (UVA), older age, WBC ≥30×10⁹/L, BCR::ABL1-like/JAK-STAT activated disease, and TP53 alterations were associated with inferior EFS when including all frontline treatments. Treatment-specific analyses demonstrated inferior EFS with TP53 alterations following PIR (HR 2.51, p<0.001), BCR::ABL1-like/JAK-STAT activated disease following blin in the R/R or frontline induction setting (HR 1.77, p=0.003), and RTK/RAS alterations following HCT any time in their treatment course (HR 1.42, p=0.021), whereas blin consolidation in CR1 improved EFS after both hCVAD (HR 0.70, p=0.024) and PIR (HR 0.39, p<0.001) on UVA. TP53 alterations consistently predicted inferior OS following PIR (HR 3.91, p<0.001), blin (HR 2.63, p<0.001), InO (HR 2.17, p<0.001), and HCT (HR 2.81, p<0.001), whereas cell-cycle pathway alterations were associated with inferior OS following hCVAD (HR 2.05, p=0.014), blin (HR 2.09, p=0.001), InO (HR 1.72, p=0.013), and CAR T-cell therapy (HR 2.99, p<0.001). Kaplan–Meier analyses demonstrated early and persistent separation of both EFS and OS curves according to TP53 status. Cell-cycle pathway alterations showed several treatment-specific associations with CR and OS, but these findings were not consistently observed across treatment cohorts. RTK/RAS, myeloid-associated, and epigenetic alterations showed limited or inconsistent associations with treatment response and survival.
Conclusions
TP53 emerged as the most robust and consistent non-ICC-defining genomic biomarker, demonstrating adverse prognostic associations across multiple contemporary treatment modalities. These findings suggest that routine NGS may provide clinically meaningful prognostic information beyond current ICC classification, particularly through identification of TP53 alterations, while highlighting potential treatment-specific effects of cell-cycle pathway alterations that warrant prospective validation.
DISCLOSURES
Tamer Othman, MD: No relevant conflicts of interest to declare.